The industrialization of pharmacogenomics for psychiatric disorders

D. Pickar

Research output: Contribution to journalArticlepeer-review


The clinical impact of pharmacogenomics in psychiatry has been limited. Part of the problem is the "mismatch" between the precisions of genotyping and the generally weak clinical databases which have been used. It will be unlikely that pharmacogenomics will reach its promise until an inherent industrialization takes place in which high throughput genotyping is applied to controlled, large scale clinical trials. Intramural NIMH double-blind placebo controlled prospective investigation of clozapine in which superiority is demonstrated for clozapine in comparison to typical antipsychotics in both positive and negative symptoms (p

Original languageEnglish (US)
Pages (from-to)467
Number of pages1
JournalAmerican Journal of Medical Genetics - Neuropsychiatric Genetics
Issue number4
StatePublished - Aug 7 2000
Externally publishedYes

ASJC Scopus subject areas

  • Genetics(clinical)
  • Neuropsychology and Physiological Psychology
  • Neuroscience(all)


Dive into the research topics of 'The industrialization of pharmacogenomics for psychiatric disorders'. Together they form a unique fingerprint.

Cite this